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The therapeutic efficacy of monoclonal antibodies (mAbs) is dependent on their glycosylation patterns. As the largest
group of currently approved biopharmaceuticals, the microheterogeneity in mAb oligosaccharide profiles deriving from
mammalian cell production is a challenge to the biopharmaceutical industry. Disengaging the glycosylation process
from the cell may offer significant enhancement of product quality and allow better control and reproducibility in line
with the Quality-by-Design paradigm. Three potential designs of an Artificial Golgi reactor implementing targeted
sequential glycosylation of mAbs are proposed including a (1) microcapillary film reactor, (2) packed bed reactor with
nonporous pellets, and (3) packed bed reactor with porous pellets. Detailed mathematical models are developed to pre-
dict their performance for a range of design and operational parameters. While all three reactor designs can achieve
desired conversion levels, the choice of a particular one depends on the required throughput and the associated cost of
enzymes and co-substrates. VC 2016 American Institute of Chemical Engineers AIChE J, 62: 2959–2973, 2016
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Introduction
Almost a quarter of all biopharmaceuticals currently being
approved are monoclonal antibodies (mAbs), with the number
of successful products per year steadily increasing.1 This dom-
inant and most lucrative group of drugs, primarily targeting
inflammatory and autoimmune conditions and cancer, is the
focus of this work. Many contemporary protein biotherapeu-
tics carry covalently attached sugar chains (oligosaccharides
or glycans) coupled to the protein backbone through either ser-
ine or threonine residues in O-linked glycosylation or via the
asparagine in the Asn-X-Thr/Ser recognition sequence in N-
linked glycosylation. mAbs are not exempt from this: the dis-
crete composition of the N-linked sequences at Asn297 can
modulate the function and efficacy of the drug as well as prop-
erties such as folding and stability of the protein backbone,
serum half-life, and protease degradation—ultimately impact-
ing product safety.1,2 It is therefore not surprising that glyco-
sylation is one of the most important critical quality attributes
(CQAs) in the manufacture of glycoproteins. The efficacy of
individual glycan structures is still largely unknown due to the
inability to produce most glycoforms individually and test
them in vitro. There are, however, certain structures (e.g., high
mannose species) that are known to be immunogenic as well
as others that are desirable for specific modes of action. Exam-
ples of the latter include afucosylated structures, which
can increase antibody-dependent cell-mediated cytotoxicity
(ADCC), and structures terminating in galactose, which
increase complement dependent cytotoxicity (CDC).3
Currently, there is a push for the application of the Quality-
by-Design (QbD) paradigm in the pharmaceutical industry.4,5
This approach advocates the simultaneous development of a
product and its manufacturing process, ensuring the identified
CQAs are achieved through informed and adequate implemen-
tation of every production step with controllable critical pro-
cess parameters (CPPs) and material attributes (CMAs),
resulting in a drug with predefined safety, efficacy, and quali-
ty. This can be accomplished through prior experimentation,
gathering of biological and physicochemical data relevant to
cell cultures and any pre or postprocessing involved, and their
statistical analysis and modeling to gain clear understanding
of the responses of biological and artificial systems within the
manufacturing sequence. This knowledge then governs and
shapes possible design strategies within the QbD approach.
The production of glycoprotein therapeutics is dominated by
mammalian expression systems for the production of biophar-
maceuticals,1 due to the higher safety and efficacy of products
derived from these systems. Even though these systems allow
the production of human-like glycosylation patterns, the result-
ing product is usually highly heterogeneous depending on the
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presence or absence of some sugars, so a significant fraction of
antibodies may be less effective than desired.6,7
Future research to combat glycan heterogeneity has two
paths: in vivo and in vitro glycoengineering. With the publica-
tion of the draft Chinese hamster ovary (CHO) cell genome in
20118 and new CRISPR/Cas9-mediated genome engineering
tools,9 the glycosylation capacity of CHO cell factories could
be tailored. Alternatively, prokaryotic10 and lower eukaryotic
cell factories11,12 have been progressively engineered to mimic
the mammalian glycoform more closely. This would require
optimal expression levels of glycosyltransferases, the enzymes
required for nucleotide-sugar donors (NSDs) synthesis, trans-
port proteins, and cofactors all correctly localized within the
cell, which is difficult to achieve. Such systems offer much
faster cell growth and product expression rates; they are less
sensitive to mechanical stress and require much simpler medi-
um formulations, typically offering a less costly protein expres-
sion platform.
A significant enhancement both in product quality and quan-
tity could be achieved by combining the benefits of expression
from nonmammalian hosts with antibody glycosylation per-
formed in vitro in an Artificial Golgi reactor (AGR). Instead of
attempting to orchestrate optimization across the cell’s glyco-
sylation pathway, ex vivo glycosylation can build an oligosac-
charide structure in a controlled fashion, which, in principle,
can afford full control over the resulting glycan distribution to
meet the CQAs in line with the QbD paradigm. Equally, an
AGR can follow a traditional mammalian cell-based production
step to narrow the product glycoform distribution. A previously
proposed approach to this consists in glycosylation remodeling
through trimming off the heterogeneous N-glycans and transfer-
ring presynthesized sugar chains from glycan oxazolines to Fc-
deglycosylated antibodies by enzymatic glycosylation.13 The
concept of AGR was first mentioned in the context of enzymat-
ic modification of glycosaminoglycans (specifically the 3-O-
sulfonation of heparan sulfate) using a digital microfluidic plat-
form.14 However, this approach is suitable only for small-scale
experiments since it relies on individually controlled droplets
carrying nanoparticle-bound substrate and enzyme/cofactor and
makes strictly sequential enzymatic modification very problem-
atic because of its use of dissolved enzymes.
Herein, we propose an approach to the design and optimiza-
tion of modular artificial reactors performing step-by-step oli-
gosaccharide modifications, illustrating the effects of various
operational parameters on their optimal configuration. The lat-
ter is determined as the one that affords a predefined conver-
sion level of a yeast-derived mAb assumed to be carrying an
initial Man5 structure into a single target glycoform. These
results will help guide the construction of a prototype system,
the empirical data from which will feed into the design and
validation cycle that underpins QbD.
N-Linked Glycosylation of mAbs
N-linked glycosylation of mAbs has been studied exten-
sively. Jimenez del Val et al.15 have reported a reaction net-
work relevant to mAb glycosylation, which is limited to
complex bi-antennary structures due to steric hindrance. We
envision that the AGR could begin with the Man5 glycan
bypassing the initial stages of glycan processing involving the
trimming of the Man9 structure down to Man5 by ManI. This
is in keeping with the use of Pichia pastoris SuperMan5 as an
expression host, a commercially available strain for the high-
yield expression of recombinant proteins with a Man5 glyco-
form. This has been engineered by disrupting the native Och1
gene, the origin of hypermannosylation in P. pastoris glycans,
with the a1,2-mannosidase from Trichoderma reesei. We also
removed the Man4 glycan and all its descendants in light of
recent evidence indicating that the enzyme ManII performs
the two trimmings of mannose residues without dissociation of
the intermediate16 (see below). Thus the reaction scheme of
mAb glycosylation of Jimenez del Val et al. has been reduced
to Scheme 1.
Scheme 1. N-linked glycosylation reaction tree spawning from one precursor oligosaccharide, Man5GlcNAc2, with
61 glycans and 78 reactions.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Clearly, a mAb product formed through a series of reactions
in Scheme 1 would consist of a mixture of glycans with differ-
ent stabilities and therapeutic efficacies. Indeed, the presence
of core fucose has been shown to decrease ADCC by up to 50
times,17,18 while high mannose structures may affect serum
half-life and are potentially immunogenic.19,20 Terminal
galactose moieties have been reported to enhance
complement-dependent cellular cytotoxicity21 and terminal
sialic acid motifs are known to enable anti-inflammatory prop-
erties of mAbs.22 An important contributing factor to the high
diversity of glycans is the low degree of spatial segregation of
enzymes in the Golgi apparatus, which enables reaction path-
ways that would have been impossible had the enzymes acted
strictly sequentially. However, this complete spatial segrega-
tion can be achieved easily in an artificial system to direct gly-
cosylation toward a desired product.
Below, we exemplify the concept of the AGR employing
just four immobilized enzymes (GnTI, ManII, GnTII, and
GalT), which, when applied sequentially, lead to the reaction
network shown in Scheme 2. This network involves just nine
glycans, nine reactions, and three terminal species. However,
careful design and optimization of the AGR allows, in
principle, maximization of the production of the target bi-
galactosylated oligosaccharide, making the fraction of by-
products negligibly small.
Enzyme kinetics
GnTI, GnTII, GalT. Glycosyltransferases GnTI, GnTII, and
GalT perform the addition of GlcNAc and Gal residues using
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and
uridine diphosphate galactose (UDP-Gal) as NSDs, respective-
ly. The mode of action of these enzymes is consistent with the
sequential bi–bi reaction mechanism including competitive
and product inhibition as reported by Jimenez del Val et al.,15
which in general can be represented as:
Note that competitive inhibition is only relevant to GalT,
which simultaneously catalyses the galactosylation of six
different substrates in Scheme 2, while GnTI and GnTII have
just one substrate each in this context. The corresponding reac-
tion rate expressions were also derived by Jimenez del Val
et al.:15
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where ½E0 is the total concentration of an enzyme, UDP is uri-
dine diphosphate, and the summations in the denominator are
taken over all the substrates (first sum) and products (second
sum) relevant to this enzyme. The other quantities in (2)
denote the concentration of a NSD; catalytic rate constant,
kEcat, specific to enzyme E and possibly substrate OSi; dissocia-
tion constant of enzyme-NSD complex, KENSD; dissociation
constants of enzyme-reactant and enzyme-competing oligo-
saccharide complexes, KEi and K
E
j ; dissociation constants of
enzyme-product complexes, KEj11; and that of enzyme-UDP
complex, KEUDP (see reaction mechanism (1)).
aManII. The trimming of two mannose residues from the
Man5GlcNAc3 oligosaccharide is performed by ManII without
dissociation of the intermediate.16 The reaction mechanism
can be summarized as
which is equivalent to Michaelis-Menten kinetics with prod-
uct inhibition. The corresponding rate expression is of the
form:
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The meanings of the symbols in (4) are the same as in (2)
above.
Reactor Design
Considering the above, an AGR should afford: (1) modular-
ity based on a sequential arrangement of reactor compartments
each featuring a single immobilized glycosyltransferase/glyco-
sidase, which directly implies (2) a smaller number of possible
Scheme 2. Reaction scheme corresponding to sequential action of the enzymes GnTI-ManII-GnTII-GalT.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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glycans dictated by the employed enzymes and their sequence,
(3) better control and targeting of the glycosylation process,
and (4) better reproducibility.
For reaction Scheme 2, a narrow glycan distribution output
can be achieved by choosing design and operational parame-
ters to ensure sufficiently high conversion of oligosaccharides
in each of the reactor compartments (Figure 1).
The enzymes are one of the most costly elements of the
reactor, so their immobilization is crucial to the design. Cova-
lent chemical bonding or physical adsorption techniques can
be employed as appropriate to the type of support as discussed
below.
AGR designs considered here are assumed to operate in
per-batch mode, so the fermentation product is flowed through
an AGR, the volume of which is normally much smaller than
the volume of the batch, so the reactor can be treated as oper-
ating continuously for the purposes of its modeling and opti-
mization. For a continuous flow reactor (Figure 1), it is
important to find the right balance between the rates of (mac-
roscopic) flow, diffusional transport toward enzyme-lined sup-
port surfaces, and enzymatic conversions themselves. In the
present case, it is the slow local diffusional transport of large
mAb molecules and relatively slow reaction kinetics that act
as rate-limiting steps, which determine the residence time
required to reach desired conversion levels. With this in mind,
we consider the following reactor configurations, which afford
acceptable diffusion times from the bulk of flowing solution to
immobilized enzymes:
 microcapillary film reactor (MCFR)
 packed bed reactor with nonporous spherical pellets
(PBRnp)
 packed bed reactor with porous spherical pellets (PBRp)
In the following sections, we consider these reactor types in
more detail, including the formulation of the relevant mathe-
matical models involving a detailed description of mass trans-
port in each case.
MCFR
This reactor type is enabled by the availability of highly
reproducible microcapillaries that can be manufactured to
practically arbitrary length in the form of plastic microcapil-
lary films (MCFs).23,24 MCFs can generally be operated at
higher flow rates and lower pressure drops than PBRs, but
offer a smaller surface area (relative to reactor volume) avail-
able for the binding of effector enzymes.
Axial transport of species in this system is provided by
forced convection, while radial transport toward enzyme-
covered walls is purely diffusional. This reactor is considered
to be operated only under convection-dominated conditions in
the laminar flow regime (see below), so the mass balance
equations for all species take the form:
@ci
@t
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where ci is the molar concentration of species i (including all
the relevant mAb glycoforms, UDP-GlcNAc, UDP-Gal, and
UDP), Di is its molecular diffusion coefficient, and vz is the
flow velocity profile, which for viscous flow in a circular
capillary under laminar conditions is described by the follow-
ing equation25:
vzðrÞ5v0 12 r
2
r20
 
(6)
where v05Q=pr205vs=2 is the center-line velocity, r0 is the
radius of the capillary, Q is the volumetric flow rate, and vs is
the superficial (or average) flow velocity.
The assumption of convection-dominated conditions is jus-
tified if the Peclet number,25 defined as Pe5vsr0=DmAb (where
DmAb is the common diffusion coefficient of mAbs), is consid-
erably larger than unity. Under such conditions, the axial dif-
fusion term becomes negligible compared to the other terms in
the mass balance equation and can be eliminated. Given that
DmAb can be as low as 531027 cm2s21 (see below) and the
typical radius of a microcapillary is in the range r05502
100 lm, flow velocities as low as >1 lm s21 are already suffi-
cient to ensure a convection-dominated regime.
The boundary conditions complementing equations (5) for
all species are as follows:
Inlet, z50, 0  r  r0:
ci5c
in
i (7)
where cini are the inlet concentrations of all the species (only
the initial oligosaccharide Man5 and NSDs have nonzero inlet
concentrations).
Centre-line, 0 < z  L, r50:
@ci
@r
50 (8)
due to the cylindrical symmetry.
Capillary wall, 0 < z  L, r5r0:
Di
@ci
@r
5Ri (9)
where the overall reaction terms for each species i are defined
as Ri5
PNR
j51 mijrj, where mij is the stoichiometric coefficient of
species i in reaction j (in accordance with Scheme 2), rj is the
reaction rate given by a rate expression of the form (2) or (4),
respectively, depending on the enzyme effecting this reaction,
and NR is the total number of reactions.
It should be noted that surface concentrations of immobi-
lized enzymes in the reaction terms in (9) are assumed to be
nonzero and equal to their monolayer concentrations only
within the corresponding reactor compartments (note that it
has been found that for many enzymes the minimum loading
to achieve the highest activity retention is equivalent to the
formation of a monolayer26,27).
Finally, the pressure drop along a cylindrical capillary
obeys the Hagen-Poiseuille equation:25
Figure 1. Schematic representation of an AGR imple-
menting reaction Scheme 2.
[Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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where l is the dynamic viscosity of the solution and L is the
total reactor length.
PBRnp
Considering a packed bed reactor (PBR), we assume that
(1) it is filled with spherical pellets with a uniform size distri-
bution such that the pellets are immobile (fixed bed), (2) their
size is much smaller than the diameter of the tube, so that (3)
flow irregularity near the walls of the reactor can be ignored,
and hence (4) there are no radial gradients of either flow veloc-
ity or concentrations, and (5) the enzymes cover the surfaces
of pellets uniformly at their monolayer concentrations within
respective reactor modules.
As for the MCFR, the mass transport in the PBRnp is gener-
ally convection-dominated (considering that pellet sizes are
approximately the same as microcapillary diameters). Howev-
er, we have kept the diffusion term to ensure the simulation
results are valid in all possible test cases. It follows from the
above assumptions that concentration distributions of all the
species are homogeneous in every cross-section perpendicular
to the column axis, so any radial terms can be ignored. Thus,
mass transport and reactions can be described by the following
equation:
ebed
@ci
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Di
@2ci
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where ebedsbed Di is the effective diffusivity of species i in the
packed bed medium at low Reynolds numbers (ebed being the
bed porosity and sbed its tortuosity
28,29), and qi is the effective
reaction term due to the enzymatic reactions taking place on
the surfaces of randomly packed support pellets.
When diffusion in the interparticle space is insufficiently
fast relative to the flow velocity and pellet size, species con-
centration distributions are not uniform within the fluid phase
and diffusional resistance must be taken into account when
formulating the effective reaction term qi. This is macroscopi-
cally described by the dimensionless Sherwood number, Sh,25
relating the total rate of mass transfer to the rate of diffusion
alone. The local Sherwood number relevant to a particular spe-
cies (owing to the drastically different diffusivities of mAbs
and NSDs) in a packed bed is defined as:
Shi5
jidpart
Di
(12)
where ji is the respective mass-transfer coefficient and dpart5
2rpart is the particle diameter. There exist a number of analyti-
cal, semi-analytical, and empirical correlations describing the
dependence of the Sherwood number on the mass transport
and bed parameters.25,30–35 We use here the one derived
recently by Scala34 for low Reynolds number flows, which
corresponds to the conditions expected in a packed bed AGR:
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where Re5qvsdpart=l is the Reynolds number and Sci5l=qDi
is the Schmidt number,30 q being the fluid density. The effec-
tive reaction term qi in (11) is then equal to the rate of trans-
port of reactants to/from the pellet surfaces through a
boundary layer formed around them due to convection:
qi5
12ebed
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3 ð12ebedÞShiDi
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where Apart54pr2part is the pellet surface area, Vpart5
4
3
pr3part is
its volume (note that ð12ebedÞ=Vpart represents the number of
pellets in a unit volume of the reactor), and csi is the concentra-
tion of species i in the immediate vicinity of the active pellet
surface, while ci denotes the average concentration in the fluid
bulk at points equidistant from adjacent pellet surfaces. At
equilibrium (assumed to be established quickly at any point
along the reactor), the rate of mass transfer toward the surface
of a pellet equals the reaction rate at the surface so that
ShiDi
dpart
ðci2csi Þ5Rsi (15)
where Rsi are the reaction terms (see explanation after Eq. 9)
with surface concentrations csi substituted in place of bulk
concentrations.
The model for the PBRnp is completed by the inlet condi-
tions of the form (7) and “no-change” conditions @ci=@z50 at
the reactor outlet.
PBRp
Replacing nonporous support pellets with porous ones
brings an additional assumption that the enzymes line the pore
walls uniformly at their monolayer concentration. The mass
balance equation (11) holds also for porous support pellets.
Additionally, concentration distributions in the interparticle
space must be coupled with those arising within the pellets
owing to the diffusion of species along the pores and reactions
catalyzed by enzymes lining pore walls. The corresponding
mass balance equation within a porous particle is:36
epart
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where cparti denotes the concentration of species i within parti-
cle pores as a function of distance r from the particle center
and time, Dparti 5Diepartdi=spart is the diffusivity of species i in
the pores of a porous support particle, epart is the particle
porosity, di5ð12ri=rporeÞ4 is the constrictivity of the particle
pores toward species i where ri is the molecular radius of this
species, and spart is pore tortuosity.
29,37 The last term in (16)
represents the reaction contribution from the pore walls aver-
aged over the pore cross-section (diffusion perpendicular to
the pore axis is assumed instantaneous). Rparti denotes reaction
terms for every species (see comment after Eq. 9) with the
substitution of interparticle concentrations cparti .
The reaction rate in Eq. 14 describing interparticle mass
transport remains the same when nonporous particles are
replaced with porous ones, but “surface” concentrations csi
now denote effective concentrations at the pore entrances, i.e.,
csi5c
part
i jr5rpart . The second condition coupling the concentra-
tion fields outside and inside porous support pellets is provided
by imposing the conservation of flux between the two media:
Dparti
@cparti
@r

r5rpart
5
ShiDi
2rpart
ðci2csi Þ (17)
Note that differential equations (16) for all species i together
with boundary conditions (17) and equations (14), which pro-
vide a link with Eq. (11) describing concentrations outside the
support particles, apply at every position z along the reactor.
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The closing relations at the inlet and the outlet of the reactor
are the same as for the PBRnp.
Pressure drop in PBRs
Regardless of the type of support particles (porous or non-
porous), the pressure drop in PBRs is well described by the
Ergun equation:25,38
DP5
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(18)
Attainable enzyme loadings for different reactor designs
Let us estimate the average amounts of enzyme that can be
adsorbed per unit reactor volume on the reactor walls
(MCFR), on particle surfaces (PBRnp), or on pore walls with-
in porous particles (PBRp). We assume that in all these cases
the enzyme covers the respective surfaces with the density
defined by the monolayer coverage denoted as CsE (obviously,
different enzymes may have different values).
Then for the MCFR:
½EMCFRavg 5
AwallC
s
E
Vreactor
5
2pr0LC
s
E
pr20L
5
2
r0
CsE (19)
where Awall is the total capillary wall surface area and Vreactor
is the total reactor volume.
For the PBRnp the amount of enzyme on the surface of one
particle is multiplied by the number of particles per unit
volume:
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Finally, for the porous particles of the PBRp the pore wall sur-
face area per particle is multiplied by the number of particles
per unit reactor volume and the enzyme surface concentration:
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Owing to the generally valid relationship ðr0ÞMCFR  rpart >>
rpore, the average enzyme loading in the PBRnp is typically
comparable to that in the MCFR, while that in the PBRp great-
ly exceeds the enzyme loadings in both the MCFR and
PBRnp. Indeed, since pore sizes are normally at least three
orders of magnitude smaller than particle sizes (tens of nano-
meters vs. tens (or hundreds) of microns, respectively) the
resulting enzyme loadings can also differ proportionally (tak-
ing the same size of porous and nonporous particles). Natural-
ly, this is only true provided the same enzyme coverage is
achievable throughout the porous particles, whereas in reality
a fraction of pores or their sections in the vicinity of the parti-
cle core may be inaccessible for enzyme immobilization.
Additionally, the enzyme coverage attainable within the pores
may not be as high as those achieved in other reactor types
owing to steric hindrance imposed by surface curvature of the
pores. Furthermore, diffusion of large mAb molecules inside
the pores can be tangibly slower than in the solution bulk, thus
reducing the advantage of having higher effective enzyme
concentration. Nevertheless, the above expressions provide a
qualitative guide to the maximum achievable reaction rates in
each case.
Optimization of reactor parameters
An optimal reactor design must in general satisfy several,
sometimes conflicting, criteria. On one hand achieving the
highest throughput is desirable. On the other hand, the product
quality must be ensured as stipulated by the QbD paradigm.
To satisfy the first requirement one seeks to minimize the resi-
dence time of reactants within the reactor and enhance
throughput by increasing the flow rate. The second criterion
(viz., the output glycoform distribution) can be ensured by
imposing a threshold for the conversion of the initial glycan
Man5GlcNAc2 into the final product Man3GlcNAc4Gal2
(Scheme 2). In the following, we demand that 95% of the ini-
tial glycan is converted into the target product, although this
threshold can be set arbitrarily.
One of the challenges of the sequential design is that the
overall yield decreases geometrically with the number of
stages. Hence, to attain the required overall yield, the yields of
individual reactor modules must be sufficiently high, which
can be ensured by choosing appropriate residence times within
the modules (or, equivalently, their lengths).
Thus, we choose the reactor module lengths as the variables
in the following optimization problem for each reactor type:
s ! min
L1;L2;L3;L4
s:t: ½Man3GlcNAc4Gal2ðLÞ=½Man5GlcNAc2in  0:95
(23)
where the total residence time is defined for any reactor design
as s5L=vs, with Li the reactor module lengths and L5
P
i Li.
To compare the three reactor types, we consider their opti-
mized designs and examine the effects of the remaining design
and operational parameters (i.e., the flow rate, capillary, parti-
cle and pore radii, and excess of NSDs) on the minimum resi-
dence time required to achieve 95% conversion, denoted
s95%, as well as on the corresponding Li values and pressure
drop along the reactor.
When optimizing a practical reactor design, other potential
constraints, such as an upper bound for the pressure drop per-
mitted by the reactor hardware or bounded lengths of reactor
modules or of the whole reactor, must be considered. They
have not been incorporated in the formulation of the minimi-
zation problem (23) to afford greater generality of the reported
results and reveal the parametric variations in these quantities.
Clearly, a next step could be detailed design of the most prom-
ising reactor configuration (given the scale and throughput
required), where these finer details can be resolved.
Parameter Values
Numerical values of reaction, design, and process parame-
ters employed here come from a variety of sources, and not all
of them may represent practically achievable ranges, although
the aim was to select the most realistic values possible.
Enzyme kinetics were adopted from the literature15 and corre-
spond to the reactivity of free enzymes (Table 1). Clearly,
enzyme immobilization, especially in nanopores of porous
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support particles, may alter their kinetic parameters drastical-
ly. Furthermore, the pH and temperature dependence of these
kinetics would need to be assessed to establish how these
parameters can be controlled inside reactor compartments to
maximize conversion. The pH value (or distribution) may also
affect enzyme binding to the support. These effects will be
examined more closely in future work along with potential
enzyme degradation/loss of activity.
Monolayer concentrations of all the enzymes were estimat-
ed assuming a spherical shape and square packing on the sup-
port surface (CsE5ð2rEÞ22N21A where rE50:066 MW1=3E is the
radius [nm] of a spherical enzyme molecule of molecular
weight MWE
39 and NA is Avogadro’s constant). The values
used in the simulations (Table 2) were computed on the basis
of enzyme data reported by Jimenez del Val et al.15
The mAbs concentration was taken to be commensurate
with quantities achievable using nonmammalian cell cultures,
i.e., in excess of 1 g/L.40 Therefore, cinmAb510 lM was
adopted as the nominal value in the simulations. If, however,
one takes into account a potential capture and concentration
step preceding in vitro glycosylation, mAb concentration at
the inlet of an AGR can be substantially higher reaching,
e.g., values of the order of 18 g/L41 corresponding to cinmAb 
100 lM. The effect of such a preconcentration step on reactor
designs will be considered below.
The amounts of NSDs required for the complete glycosyla-
tion of antibodies are dictated by the stoichiometry of the reac-
tions in Scheme 2. Hence, the minimum concentrations of
both UDP-GlcNAc and UDP-Gal are double the concentration
of mAbs. However, to ensure higher reaction rates and lower
residence times NSDs should be in excess of their stoichiomet-
ric requirements. Therefore their inlet concentrations are rep-
resented as
cinUDP	GlcNAc5ð21eUDP	GlcNAcÞ cinmAb (24a)
cinUDP	Gal5ð21eUDP	GalÞ cinmAb (24b)
where eUDP	GlcNAc and eUDP	Gal are the relative stoichiometric
excess values of the respective NSDs.
The diffusivity of mAbs in aqueous solutions was taken as
DmAb55310
27 cm2s21 in accordance with the results of Netti
et al.42 Note that this applies for unrestricted diffusion in the
absence of steric hindrance. Effective diffusivity in a packed
bed or inside nanopores of porous pellets may be slower (see
above) depending on the bed or pellet porosity and pore tortu-
osity (see below).
The packed bed parameters were adopted from a family of
porous Amberchrom
VR
resins which are extensively used in the
pharmaceutical and chemical industries.43 The particle sizes
are 20–160mm (assumed the same for the PBRnp and PBRp to
facilitate their comparison) with pore sizes of 150–1000 A˚,
offering a broad variety of mass transport conditions for the
AGR. The average value of porosity of Amberchrom
VR
resins
is epart50:6 and pore tortuosity is spart52.
44 The porosity of
the packed bed itself was taken as ebed50:367, which corre-
sponds to the average value for random close packing of
spheres.45 The value of bed tortuosity, sbed, was calculated as
1.8 based on ebed according to Lanfrey et al.
28
The solution density and viscosity were taken equal to those
of water at 30 8C (owing to relatively low concentrations of
mAbs and NSDs), i.e., q51 g=mL and l50:7978 mPa  s.
To study the variations in the optimal reactor configuration
(i.e., s95%, pressure drop, and Li) induced by changes in each
of the remaining parameters we select a nominal configuration
providing a reference point for each reactor type. The values
vs50:1 cm=s, eUDP	GlcNAc51, eUDP	Gal51 were chosen to be
the same for all reactor types as well as r0575 lm for the
MCFR, rpart537:5 lm for both the PBRp and PBRnp and rpore
525 nm for the PBRp.
Results and Discussion
MCFR
The results presented below illustrate and quantify the
effects of varying each of the parameters vs, r0, and
eUDP	GlcNAc one-at-a-time since they represent entirely differ-
ent design and operation decisions. This also allows a simpler
rationalization of the observed dependences.
Let us first consider the effect of vs on the residence time
required to achieve 95% conversion in the MCFR while keep-
ing the other parameters at their nominal values. As expected,
s95% is independent of vs (Figure 2a). There is no diffusion
effect on s95% since diffusion times needed to transport reac-
tants and products to/from the capillary wall surface remain
the same regardless of the convection rate. However, increas-
ing vs while preserving the same residence time implies that
reactor compartment lengths must also increase proportionally
(Figure 2b).
This simultaneous increase in vs and reactor length leads to
a quadratic increase in the pressure drop driving the solution
through the MCFR. Thus, DP can quickly reach critical values
permitted by the system, hence limiting the maximum attain-
able throughput.
Figure 3 demonstrates the effect of the capillary radius on
s95%. Increasing r0 leads to an increase in diffusion time from
the core of the capillary to the enzymes immobilized on its
walls. Notably, the corresponding increase in residence times
is almost linear (instead of the expected quadratic behavior)
owing to the relatively slow reaction kinetics, which are a sig-
nificant limiting factor despite the rather low diffusivity of
mAbs.42 In this case too, the lengths of individual reactor com-
partments increase (almost) linearly with the capillary radius
(Figure 3b).
Last, we look at the effect of eUDP	GlcNAc on s95% and the
lengths of individual reactor modules. Figure 4 illustrates that
eUDP	GlcNAc has a significant effect on s95% since a high
Table 1. Kinetic Parameters of Enzymes Examined
Enzyme kEcat ðs21Þ KEj ðlMÞ KENSD ðlMÞ Substrates
GnTI 17 260 170 Man5GlcNAc2
ManII 32 200 – Man5GlcNAc3
GnTII 23.4 190 960 Man3GlcNAc3
GalT 14.5 130 65 Man3GlcNAc4
14.5 430 65 Man3GlcNAc4Gal
(a-1,3 branch)
14.5 6280 65 Man3GlcNAc4Gal
(a-1,6 branch)
Table 2. Molecular Weights14 and Monolayer Concentrations
of Enzymes
Enzyme MW (Da) Concentration (pmol/cm2)
GnTI 51,600 6.9
ManII 285,000 2.2
GnTII 200,000 2.8
GalT 44,040 7.6
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conversion level has been imposed. Thus, a stoichiometric
excess of UDP-GlcNAc equal to the amount of mAbs
(eUDP	GlcNAc51) provides a decrease in s95% of over 40%
compared to a no-excess situation (Figure 4a). Regarding the
corresponding changes in Li (Figure 4b), the strongest varia-
tion is experienced by L3 (i.e., the module containing GnTII)
while the variation in L1 is much more moderate. This is
because the effective relative stoichiometric excess in the first
(GnTI) module is 11eUDP	GlcNAc, but only eUDP	GlcNAc in
the third module (since an amount of UDP-GlcNAc almost
equal to the amount of mAbs is consumed in the first module).
The changes in L2 and L4 are “compensatory” because the
operation of these modules is independent of UDP-GlcNAc
but the solution to the optimization problem (23) corresponds
Figure 4. Dependence of (a) s
95% and (b) reactor module lengths of the MCFR on eUDP	GlcNAc for r0575 lm.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2. Effect of superficial flow velocity on (a) residence time and pressure drop, and (b) reactor module lengths
under otherwise nominal conditions in the MCFR.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 3. Variations of (a) s
95% and DP, and (b) reactor module lengths of the MCFR with capillary radius. Simula-
tions were performed for specific radii (denoted with symbols) reported in Refs. [23, 24].
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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to the minimum overall residence time. The effect of eUDP	Gal
(not shown) is similar to that of eUDP	GlcNAc but with the most
significant changes occurring in L4. We expect that the same
would apply to other NSDs (i.e., GDP-Fuc or CMP-Sia) had
other glycosyltransferases been included in the AGR.
PBRnp
Despite a very different pattern of diffusion and convection
fluxes, the results for the PBRnp (Figures 5–7) are qualitative-
ly similar to those reported for the MCFR. The dependence of
s95% on vs is not constant as for the MCFR, but its variation is
very limited. Its source is the nonlinear dependence of the
Sherwood number (13) on the flow velocity. This reflects the
decrease in the hydrodynamic boundary layer thickness within
the convoluted void of the packed bed with increasing vs,
which results in an increased diffusional transport rate toward
enzyme-lined pellet surfaces. Despite lower residence times
vs. those in the MCFR and smaller Li, the corresponding pres-
sure drop is several times higher than DP in the MCFR (Figure
5a). However, a higher throughput in the PBRnp can be
achieved at lower vs (giving acceptable pressure drops) by
increasing the diameter of the reactor column.
Changing the size of spherical support particles results in
approximately linear variations in s95% and Li, with packed
beds employing smaller pellets requiring higher pressure drops
(Figure 6).
The effect of eUDP	GlcNAc is illustrated in Figure 7. As
expected, the behaviors of s95% and Li are qualitatively simi-
lar to those for the MCFR.
Note that the obtained Li and DP values (Figures 5–7) may
appear unrealistic. However, they are reported here for the
ranges of parameters similar to those used for the PBRp and
MCFR to illustrate the important differences in performance
of the different reactor types.
PBRp
The use of porous support pellets offers a significant reduc-
tion in s95% (Figures 8–10) owing to a much higher enzyme
loading in the PBRp than in other reactor types. This also
results in smaller Li and hence, reduced DP along the reactor
required to drive the solution at the same speeds as in the
MCFR or PBRnp. The main qualitative difference from the
other reactor types is apparent from the dependence of s95%
on vs: the former drops much more noticeably as vs increases.
As the solution flows faster, the diffusional transport across
the hydrodynamic boundary layers surrounding support par-
ticles is intensified, leading to more efficient “pumping” of
reactants into the pores. Consequently, the reactants can
Figure 5. Effect of vs on (a) residence time and pressure drop, and (b) individual reactor module lengths in the
PBRnp.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 6. Variations of (a) s
95% and DP, and (b) reactor module lengths of the PBRnp with particle radius. Simula-
tions were performed for specific radii of Amberchrom (R) pellets denoted with symbols.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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penetrate deeper into the pores and encounter more enzyme,
enhancing the overall reaction rate. This is apparent in Figure
11, illustrating the concentration profiles of Man5GlcNAc2
diffusing into a porous particle located near the reactor inlet at
three different vs values. Note, however, that the reactants can-
not penetrate very far into the particle before encountering
Figure 9. Variations of (a) s
95% for three different pore sizes, and (b) reactor module lengths of the PBRp
(rpore525 nm) with rpart. Simulations were performed for specific radii of Amberchrom (R) pellets denoted
with symbols.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 7. Dependence of (a) s
95% for different particle radii and (b) reactor module lengths of the PBRnp on
eUDP	GlcNAc for rpart537:5 lm.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 8. Effect of vs on (a) residence time and pressure drop, and (b) individual reactor module lengths in the
PBRp.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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enough enzyme to achieve full conversion. Therefore most of
the enzyme immobilized within the particle core is not utilized
(see below).
As for the PBRnp, decreasing the particle size enhances
mass transport and decreases residence times (Figure 9). An
additional effect is caused by the size of the pores. As rpore
decreases, the intrapore diffusivity of mAbs also decreases
owing to steric hindrance effects, which further limits the
accessible amounts of enzymes near the pore entrances. This
obviously leads to lowered reaction rates and increased resi-
dence times (Figure 9).
The effect of eUDP	GlcNAc (Figure 10) is again qualitatively
similar to that for the other reactor types.
Effectiveness of enzymatic conversions in reactors
of different types
As indicated above, the overall rate of enzymatic conver-
sions depends not only on the absolute amount of enzymes per
unit of reactor volume but also on their accessibility and mass-
transfer resistance. To quantify the negative contribution of
these limitations the concept of the effectiveness factor of an
immobilized enzyme can be invoked.
Effectiveness indicates the extent to which enzyme immobi-
lized within the reactor is utilized compared to the situation
when diffusion resistance is nonexistent and substrates (at
their average bulk concentration) have instantaneous access to
all the enzyme located at a given position along the reactor:
Effectiveness factor
5
actual reaction rate
reaction rate in absence of diffusional resistance
Figure 12 shows the computed effectiveness for the three reac-
tor configurations under their respective nominal mAb and
NSD concentrations and capillary/particle/pore radii (see
Parameter Values section) and optimized Li (imposing the
same ratio of module lengths for all the reactor types to facili-
tate their comparison). The results are presented vs. the
Figure 11. Typical normalized concentration distribu-
tions of Man5GlcNAc2 inside a porous parti-
cle lined with GnTI.
Note that the effective diffusion layer penetrates only
as far as 1/50 of the particle radius (rpart537:5 lm,
rpore525 nm).
[Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
Figure 10. Dependence of (a) s
95% and DP, and (b) reactor module lengths of the PBRp on eUDP	GlcNAc
(rpart537:5 lm, rpore525nm).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 12. Comparison of enzyme effectiveness for the
tree reactor designs.
[Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
AIChE Journal September 2016 Vol. 62, No. 9 Published on behalf of the AIChE DOI 10.1002/aic 2969
normalized distance from the reactor inlet (the boundaries of
the four enzyme compartments are clearly visible from the
rapid variations in the curves). Evidently, the PBRp offers
extremely low effectiveness owing to slow diffusion within
particle pores (50 times slower than in free solution) com-
pared to reaction rate, which is relatively high due to signifi-
cantly larger enzyme loadings than in the other reactor
designs. Hence, the reaction layer is confined to a thin zone
close to the particle surface and a large proportion of enzyme
remains inaccessible to the substrates (see Figure 11). Howev-
er, owing to the uncertainty about the accessibility of the pores
to enzyme immobilization, the practically achievable enzyme
effectiveness may be significantly higher than reported here.
Note also that the faster the enzymatic reaction, the lower
the effectiveness factor (e.g., it is the lowest for ManII which
has the fastest kinetics). This is rationalized by the mass-
transfer resistance becoming a more critical limiting factor
with faster reaction kinetics.
Dependence on mAb concentration
As noted above in the Parameter Values section, the nomi-
nal value of mAb concentration fed into an AGR is representa-
tive of that in the supernatant at harvest and may not reflect
situations when a capture or a preconcentration step exists
upstream of the Artificial Golgi. Numerical experiments sug-
gest that adding such a preconcentration step would signifi-
cantly reduce residence times in all three reactor types as
illustrated in Figure 13. Although unexpected at first glance,
this reduction essentially reflects the bimolecular nature
(excluding the enzymes themselves as their concentrations are
assumed constant) of all the enzymatic reactions but the trim-
ming of mannose residues. Indeed, since the range of mAb
concentrations (10–100 lM) does not approach enzyme satura-
tion the rates of enzymatic conversions increase quadratically
with increasing substrate concentrations. Note that since here
we have fixed the NSD excess (see Parameter Values section)
NSD concentrations automatically increase proportionally to
that of mAbs.
Inhibitory effect of UDP on reaction kinetics
Three of the enzymes considered here follow the bi-bi
ordered sequential mechanism (1) with UDP acting as a
by-product remaining in equilibrium with the enzymes. Thus,
UDP may prevent NSDs (UDP-GlcNAc and UDP-Gal) from
binding the respective enzymes, acting as a competitive inhibi-
tor pushing the equilibrium toward the EUDP complex. The
inhibitory properties of UDP are well-known and reported in a
number of literature sources either directly indicating UDP as
an inhibitor to GnTI, GnTII, and GalT or pointing to the
enzymes’ affinity for substrate analogues.46–49
Since UDP is accumulated throughout the process of in
vitro glycosylation within an AGR and can reach concentra-
tions up to four times that of mAbs, this inhibitory effect is
aggravated toward the reactor outlet, and hence, most strongly
affects the performance of GalT. To quantify this effect we
assess the extent of the reduction in s95% assuming that UDP
can be efficiently removed (bound) as soon as it is generated.
This corresponds to imposing zero concentration of UDP
throughout the reactor (see (2) in which the last two terms
in the denominator become zero) enhancing the apparent reac-
tion kinetics of GnTI, GnTII, and GalT.
Simulation results reveal that the effect of UDP removal
from the system on s95% is not influenced by such parameters
as vs and the radii of microcapillaries of the MCFR or nonpo-
rous enzyme-supporting pellets of the PBRnp. Moreover, for
the parameter ranges considered (i.e., comparable flow veloci-
ties and values of r0 and rpart), the relative changes in s95%
and Li up on the removal of UDP are numerically practically
identical for the MCFR and PBRnp. Figure 14a illustrates the
ratios of s95% and Li when UDP is removed to their values
when UDP is accumulated in the reactor, as a function of
eUDP	GlcNAc only for the MCFR and PBRnp. Note that
Figure 13. Effect of inlet mAb concentration on resi-
dence times (and as a consequence reactor
lengths) in (a) MCFR, (b) PBRnp, and (c)
PBRp.
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eUDP	Gal has a similar, but less pronounced, effect (not shown).
Conversely, the results for the PBRp demonstrate variations
with all the parameters vs, rpart,rpore, eUDP	GlcNAc, and eUDP	Gal,
albeit extremely mild. Thus, Figure 14b shows only the stron-
gest variation of the results for the PBRp with eUDP	GlcNAc.
The reduction of s95% due to the removal of UDP is sub-
stantially more significant for the MCFR and PBRnp (i.e., by
up to 27%) than for the PBRp (7%). This is unsurprising
since the much greater effective concentrations of the enzymes
available in the PBRp make the inhibitory effect of UDP rela-
tively less significant.
Considering the variations in Li, the most tangible effect of
UDP removal is on L4 for all reactor types.
A more efficient strategy of dealing with the build-up of
UDP would consist of its recycling to regenerate at least one
of the NSDs through an appropriate enzymatic pathway.50,51 If
such a strategy were to be implemented in situ, this would
allow for a significant reduction in both the lengths of reactor
compartments and running costs associated with extremely
expensive NSDs.
Discussion and Conclusions
Three potential configurations of an AGR have been pro-
posed to achieve targeted in vitro glycosylation of mAbs.
All three designs are based on a sequential application of
enzymes catalyzing different stages of glycosylation. Suffi-
ciently high conversion levels in each reactor compartment
are required to direct the whole process toward the desired
product and eliminate alternative pathways leading to unde-
sired terminal species. Detailed mathematical models of
mass transport and enzymatic reactions were developed for
the three reactor types to confirm they are capable of achiev-
ing desired levels of conversion of the initial Man5 glycan
into the final bi-antennary fully galactosylated structure
Man3GlcNAc4Gal2.
Exploring the dependence of residence times required to
reach 95% conversion and the corresponding reactor lengths
on the flow rate, characteristic sizes of enzyme supports
(microcapillary/pellet radii and pore radius for porous pellets),
and NSD excess allows the determination of practically feasi-
ble AGR parameters provided enzyme kinetic data are known.
Note that these data are protein-specific so that kinetic charac-
terization would need to be performed for all enzyme-
substrate couples prior to performing AGR optimization.
Therefore the presented quantitative results obtained with spe-
cific literature values should be used only as a guide to under-
standing the effects of controllable parameters on the optimal
AGR configuration and not as an off-the-shelf solution. In this
respect it should also be noted that this work does not consider
the dependence of kinetic parameters on pH and temperature
owing to the lack of pertinent information. If such dependen-
ces were available, the implications for optimal AGR design
would largely depend on whether a particular reactor type
allows for pH and temperature to be controlled locally within
each of the reactor compartments or only globally for the
whole reactor.
In this work, we do not consider any degradation (thermal
or chemical) of NSDs or enzymes leading to their loss of
activity due to the lack of relevant experimental indications
about the magnitudes of these effects. However, these factors
would need to be taken into account when designing a practi-
cal AGR implementation. Although no quantitative analysis
has been performed, qualitatively it is clear that since NSD
degradation would lead to their loss along the reactor a sensi-
ble countermeasure would be to increase their inlet concentra-
tions so that they reach the last AGR compartment in
sufficient quantities ensuring acceptable overall reaction
times. Conversely, loss of enzyme activity would translate
into a limited useful reactor life time while an AGR can deliv-
er target product satisfying specific CQAs. Once active
enzyme concentrations drop below a certain threshold ensur-
ing required conversion levels, the reactor (or some of its mod-
ules) may no longer be adequate and would need to be
replaced. Alternatively, a different operational strategy suit-
able for lower enzyme loadings (e.g., involving longer resi-
dence times) may be employed.
When designing a real-life system one must also consider
the required throughput and economic aspects. Indeed, the
benefits of using higher enzyme and/or NSD concentrations
are clear from the presented results; however, their cost may
prove prohibitive, e.g., for the PBRp which allows enzyme
loadings per unit of reactor volume 2–3 orders of magnitude
higher than the other reactor types considered. Conversely, if
high throughput must be achieved, a shorter column with low-
er pressure drop would be desirable, making the packed bed
with porous pellets preferable. Enzyme and NSD degradation
rates in comparison with required residence times would also
Figure 14. Effect of removing UDP from solution on s
95% and Li shown as ratios of these quantities with UDP
removed (UDP50) and with UDP generated stoichiometrically for (a) MCFR and PBRnp, and (b) PBRp.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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be an important factor in the economic feasibility of different
reactor designs.
Additionally, a practical reactor implementation in line with
the QbD paradigm must provide a safety margin to take into
account possible uncertainties in the concentrations of mAbs,
NSDs and enzymes as well as in other design and process
parameters. This, together with other assumptions made in the
construction of the models reported herein, will be explored
more closely in our future contributions.
Although only four enzymatic modules were considered
herein, the design concept and principles underlying the mod-
els and reactor optimization approach can be easily extended
to cover any number of reactor modules implementing individ-
ual enzymatic steps. For instance, this design approach can be
adapted to the remodeling of mAbs with heterogeneous gly-
cans derived from mammalian cell-based expression systems13
to achieve well-defined glycoforms for characterization or
within a manufacturing environment. Moreover, the scope of
the presented modeling and optimization approach is not limit-
ed to mAbs or to the glycosylation process and may find appli-
cations to enzymatic reaction design in other areas of
biochemical engineering.
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